STOCK TITAN

Cara Therapeutics Inc - CARA STOCK NEWS

Welcome to our dedicated news page for Cara Therapeutics (Ticker: CARA), a resource for investors and traders seeking the latest updates and insights on Cara Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cara Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cara Therapeutics's position in the market.

-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.61%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.86%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.05%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.96%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.72%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.34%
Tags
conferences
Cara Therapeutics Inc

Nasdaq:CARA

CARA Rankings

CARA Stock Data

41.76M
39.35M
14.58%
45.49%
4.71%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Stamford

About CARA

cara therapeutics is an emerging biotechnology company focused on developing novel therapeutics to treat pain, inflammation and pruritus. cara possesses both near-term clinical development opportunities combined with proprietary approaches to developing first-in-class novel therapeutics. cara's most advanced patented compound, cr845, is currently undergoing clinical testing for acute pain and uremic pruritus. this compound possesses analgesic, anti-inflammatory and antipruritic activities appropriate for multiple therapeutic applications. in addition, cara aims to develop a future pipeline of first-in-class molecules at novel analgesic and anti-inflammatory targets using its proprietary drug screening technology.